Technology ID

A Triple Combination HIV Microbicide

Lead Inventor
O'Keefe, Barry (NCI)
Christou, Paul (Universitat de Lleida)
Vavamka, Evangelia (Universitat de Lleida)
Capell, Theresa (Universitat de Lleida)
Therapeutic Areas
Infectious Disease
Development Stages

The HIV-positive population continues to rise despite a worldwide decline in the rates of infection caused by human immunodeficiency virus (HIV).  The HIV virus continues to spread due to a lack of effective vaccines and pre-exposure prophylaxis methods, even though the availability and effectiveness of antiretroviral therapy has helped reduce acquired immunodeficiency syndrome (AIDS)-related deaths. 

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Lleida, developed a triple combination microbicide for the prevention of HIV and other sexually transmitted diseases. The microbicide is comprised of an endosperm, the anti-HIV monoclonal antibody 2G12, and the antiviral lectins griffithsin and cyanovirin. The researchers have generated the microbicide combination in transgenic plants as an efficient and cost-effective production method. 

Competitive Advantages:

  • Low cost, stable production method
  • Stable and long-term storage compatible rice seed

Commercial Applications:

  • Effective anti-HIV microbicide with activity against other viruses as well (HSV, HCV)
Licensing Contact: